FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071628965> ?p ?o ?g. }

• W2071628965 endingPage "e156" @default.
• W2071628965 startingPage "e153" @default.
• W2071628965 abstract "To the Editors: INTRODUCTION Schistosomiasis affects more than 230 million people worldwide, 90% of whom live in sub-Saharan Africa.1 Data suggest that helminthic infections like schistosomiasis may hasten HIV progression in coinfected patients.2,3 Helminths induce chronic immune activation, shifting from a T-helper cell type 1 to type 2 immune response. T-helper cell type 2 lymphocytes downregulate cytotoxic effects of CD8+ T-lymphocytes, leading to an altered cytokine profile with increased viral replication.4–7 Studies have shown that treating ascariasis or filariasis improves CD4+ T-cell counts (CD4 counts) and viral loads in HIV-infected patients.8,9 Little research has explored the specific interaction between schistosomiasis and HIV, but 1 study yielded concerning results. Antiretroviral therapy (ART) naive HIV-infected patients with schistosome coinfection who were randomized to delayed antischistosome treatment with praziquantel after 3 months had larger increases in HIV RNA levels and greater declines in CD4 counts than patients treated immediately.10 Despite this possible interaction, schistosomiasis screening is not currently recommended for HIV-infected patients in many endemic countries, including Tanzania. Also, no study has yet assessed impact of schistosomiasis on ART response. We hypothesized that schistosome infection may adversely affect HIV-infected patients’ responses to ART. We conducted a retrospective cohort study to explore this issue at Bugando Medical Centre (BMC) near Lake Victoria in Tanzania, where schistosomiasis is hyperendemic. METHODS Study Participants This study was conducted from August to December 2011 at BMC HIV clinic. HIV-infected adults who had taken ART for 6–15 months were enrolled serially. Patients who had received praziquantel since beginning ART, or who were currently receiving antituberculous therapy and therefore had another concomitant infection that could cause CD4 decrease,11 were excluded. Data Collection Demographic information was collected by structured questionnaire. Baseline data (at ART initiation) were obtained from the patient database, including CD4 count, weight, and height. At the time of enrollment and sample collection, we measured CD4 count by FACSCount system (BD Biosciences, San Jose, CA), height, and weight. We used the World Health Organization (WHO) definition of immunological failure as either CD4 count falling below baseline or CD4 count persistently <100 cells per cubic millimeter.11 Patients provided single midday stool and urine samples. Kato-Katz stool smears were prepared using 41.7 mg templates (Vestergaard Frandsen, Lausanne, Switzerland). Five slides were prepared from different sites of each stool sample, which has a reported sensitivity comparable to examination of specimens from different days.12 A trained parasitologist quantified Schistosoma mansoni eggs per gram. Urine was examined microscopically and tested for circulating cathodic antigen (CCA) (Rapid Medical Diagnostics, Pretoria, South Africa). CCA, an antigen secreted into the bloodstream by adult schistosomes during active infection, is detectable in urine by rapid reagent test strip.13,14 Schistosome infection was defined as ova in stool or urine and/or a positive CCA test, a strategy shown to increase diagnostic sensitivity without compromising specificity for low-intensity S. mansoni infections typical of adult populations.15 Data Analysis Logistic regression models (adjusting baseline CD4 count, which we call “bivariate analysis,” and multivariate analysis adjusting for additional factors) were used to examine factors associated with immunological failure. In all models, we adjusted baseline CD4 count for more valid analyses, noting that the outcome, immunological failure, is defined as a function of baseline CD4 count. We used backward elimination, deleting variables with the largest P value one by one, to reach a final parsimonious model including all factors with P < 0.05. We used analysis of covariance to compare CD4 count increases between groups with and without schistosomiasis while adjusting for baseline CD4 count.16 Two-sided 95% confidence intervals and P values were used throughout. Data were analyzed using STATA IC/10.1 (College Station, TX). Ethics Ethical approval was obtained from BMC and Weill Cornell Medical College. Patients diagnosed with schistosomiasis immediately received praziquantel (40 mg/kg). RESULTS Patient Characteristics Of 364 eligible HIV-infected outpatients coming to clinic during the study period, 1 had received praziquantel and 10 were being treated for tuberculosis. Of the remaining 353 patients, 351 provided written informed consent, urine, and stool and were enrolled. Of these, 248 (71%) were females. The median age was 36 (interquartile range 31–43) years. More than 90% had primary school education or less and >80% were unemployed or petty traders. Baseline CD4 count at ART initiation was 173 (76–249) cells per cubic microliter and baseline body mass index (BMI) was 21.6 (19.7–23.9) kg/m2. Baseline WHO clinical stages were as follows: stage 1, 54 patients (15%); stage 2, 130 (37%); stage 3, 127 (36%); and stage 4, 40 (11%). Patients had taken ART for a median of 338 (265–376) days. Prevalence of Schistosomiasis Schistosomiasis was diagnosed in 97 patients (27.6%). All 97 were CCA positive, and 46 of 97 had ova in urine or stool. All 46 patients had S. mansoni, and 1 had concurrent S. haematobium. All 46 patients with schistosome ova were CCA positive, and 41 of 46 had low-intensity infections of <100 eggs per gram of stool. Outcomes After ART The median CD4 count change was +190 (104–303) cells per cubic microliter. Median BMI increase was +1.4 kg/m2. Twenty-five patients (7%) met ≥1 WHO criterion for immunological failure: 22 had CD4 counts below baseline and 7 had CD4 counts persistently <100 cells per cubic microliter. Factors Associated With Immunological Failure Table 1 shows univariate and multivariate analyses. In the multivariate model, education and baseline BMI were moderately associated with immunological failure (P = 0.04), whereas schistosome infection was strongly associated (odds ratio: 4.6, 95% confidence interval: 1.9 to 11.2, P = 0.0009).TABLE 1: Baseline Factors Associated With Immunological Failure in HIV-Infected Adults After At Least 6 Months of Antiretroviral TherapySecondary analysis by analysis of covariance, with change in CD4 count as a continuous outcome, showed that CD4 count increase on ART was significantly associated with schistosome infection, baseline CD4 count, and age in the multivariate parsimonious model. These effects were most strongly driven by schistosome infection status, with an estimated difference of 65.5 cells per cubic microliter in CD4 count change between those with and without schistosomiasis (P = 0.0004). Unadjusted and adjusted mean CD4 count changes were +163 versus +226 cells per cubic microliter and +161 versus +227 cells per cubic microliter, respectively. DISCUSSION Among these adult HIV-infected outpatients living in a schistosome endemic area, nearly one-third had active schistosome infection. Odds of developing immunological failure were 4 times greater in patients with schistosome coinfection. To our knowledge, this is the first study assessing the association between schistosomiasis and ART treatment failure. Our findings have major implications for ART management in millions of HIV-infected outpatients living in schistosome endemic areas who are managed based on immunological and clinical criteria because viral load measurements are not routinely available. Schistosome-infected patients also had significantly lower CD4 count increases on ART than schistosome-uninfected patients. More frequent immunological failure and smaller CD4 count gains in schistosome-infected patients could both be explained by chronic helminth-induced T-helper cell type 2 immune activation that may permit increased viral replication.4 Our work extends findings of a study in which Zimbabwean HIV- and schistosome-coinfected patients randomized to delayed praziquantel had larger HIV RNA increases and CD4 count declines than patients treated immediately.10 Other studies have suggested similar effects from other helminth infections, but not unanimously.8,9,17 Notably, other studies have not explored helminth infections' effects on patients receiving ART. Our finding that schistosomiasis is both common and associated with immunological failure supports implementation of schistosomiasis screening at ART initiation. Unfortunately, stool and urine testing alone, particularly when done as the thin preparation of stool and unfiltered urine typical of many African clinical laboratories, has low sensitivity for detecting schistosome ova. Antigen tests including urine CCA used in this study may provide rapid, more sensitive screening for schistosomiasis, particularly because HIV-infected individuals may excrete fewer eggs.18,19 Further operational research is needed to determine costs, benefits, and optimal screening strategies. In a previous study that compared baseline characteristics of schistosome-infected and uninfected HIV-positive patients, schistosome-infected patients had higher baseline CD4 counts and CD4:CD8 ratios but comparable viral loads.6 Patients in that study were ART naive as were ours during baseline investigations. Neither study observed other baseline differences between patients with and without schistosomiasis that might explain the higher CD4 counts. Schistosomiasis may cause distinct immunological alterations in peripheral blood CD4+ T-lymphocyte subsets, and these alterations may impair patients' responses to ART. Additional studies are needed to better characterize peripheral blood CD4+ T-lymphocyte subsets in HIV and schistosomiasis coinfection. The retrospective nature of our study is an ethically necessary limitation because our hypothesis could not be studied prospectively. Based on the Zimbabwean study showing worse virological and immunological outcomes in HIV-infected patients with untreated schistosomiasis, it would not have been ethical to leave schistosomiasis untreated in patients initiating ART. Another limitation was our inability to test viral loads. Without virological data, we cannot determine whether schistosomiasis was associated with immunological failure alone or with concomitant virological failure. We plan further studies using viral load testing to explore this question. In conclusion, nearly one-third of our Tanzanian HIV-infected outpatients had schistosome infection. Schistosome infection was significantly associated with immunological failure and poorer CD4 count gain after ART use. Untreated schistosomiasis may be a major cause of immunological failure among HIV-infected patients in schistosome endemic areas. Further studies are needed to investigate whether this represents an immunological phenomenon or true virological failure, and whether screening and treatment for schistosomiasis among HIV-infected patients will improve response to ART. This is an urgent finding with major implications for ART management in resource-limited settings, where choices of antiretroviral medications are limited and success of patients on first-line ART must be maximized. ACKNOWLEDGMENTS The authors thank BMC for their support. In addition, they thank the National Institute for Medical Research—Mwanza Research Centre and particularly Mr O. Kaswamila for their hard work. The sponsors were not involved in study design or the preparation of the manuscript." @default.
• W2071628965 created "2016-06-24" @default.
• W2071628965 creator A5013929805 @default.
• W2071628965 creator A5026150956 @default.
• W2071628965 creator A5032669922 @default.
• W2071628965 creator A5035160383 @default.
• W2071628965 creator A5049829595 @default.
• W2071628965 creator A5055790580 @default.
• W2071628965 creator A5064350034 @default.
• W2071628965 creator A5067639133 @default.
• W2071628965 creator A5075734443 @default.
• W2071628965 creator A5078304672 @default.
• W2071628965 date "2013-04-15" @default.
• W2071628965 modified "2023-09-28" @default.
• W2071628965 title "Schistosomiasis and Impaired Response to Antiretroviral Therapy Among HIV-Infected Patients in Tanzania" @default.
• W2071628965 cites W1633792881 @default.
• W2071628965 cites W1875952003 @default.
• W2071628965 cites W1924972785 @default.
• W2071628965 cites W1966193770 @default.
• W2071628965 cites W1978141065 @default.
• W2071628965 cites W1980005248 @default.
• W2071628965 cites W2061623382 @default.
• W2071628965 cites W2065715749 @default.
• W2071628965 cites W2072033504 @default.
• W2071628965 cites W2084277678 @default.
• W2071628965 cites W2107108433 @default.
• W2071628965 cites W2108859519 @default.
• W2071628965 cites W2124313106 @default.
• W2071628965 cites W2134658102 @default.
• W2071628965 cites W2170206314 @default.
• W2071628965 cites W2300526228 @default.
• W2071628965 cites W4250710977 @default.
• W2071628965 doi "https://doi.org/10.1097/qai.0b013e318282a1a4" @default.
• W2071628965 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3682228" @default.
• W2071628965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23760064" @default.
• W2071628965 hasPublicationYear "2013" @default.
• W2071628965 type Work @default.
• W2071628965 sameAs 2071628965 @default.
• W2071628965 citedByCount "22" @default.
• W2071628965 countsByYear W20716289652015 @default.
• W2071628965 countsByYear W20716289652016 @default.
• W2071628965 countsByYear W20716289652017 @default.
• W2071628965 countsByYear W20716289652018 @default.
• W2071628965 countsByYear W20716289652019 @default.
• W2071628965 countsByYear W20716289652020 @default.
• W2071628965 countsByYear W20716289652021 @default.
• W2071628965 crossrefType "journal-article" @default.
• W2071628965 hasAuthorship W2071628965A5013929805 @default.
• W2071628965 hasAuthorship W2071628965A5026150956 @default.
• W2071628965 hasAuthorship W2071628965A5032669922 @default.
• W2071628965 hasAuthorship W2071628965A5035160383 @default.
• W2071628965 hasAuthorship W2071628965A5049829595 @default.
• W2071628965 hasAuthorship W2071628965A5055790580 @default.
• W2071628965 hasAuthorship W2071628965A5064350034 @default.
• W2071628965 hasAuthorship W2071628965A5067639133 @default.
• W2071628965 hasAuthorship W2071628965A5075734443 @default.
• W2071628965 hasAuthorship W2071628965A5078304672 @default.
• W2071628965 hasBestOaLocation W20716289651 @default.
• W2071628965 hasConcept C142462285 @default.
• W2071628965 hasConcept C159047783 @default.
• W2071628965 hasConcept C165901193 @default.
• W2071628965 hasConcept C203014093 @default.
• W2071628965 hasConcept C205649164 @default.
• W2071628965 hasConcept C2776225656 @default.
• W2071628965 hasConcept C2779357621 @default.
• W2071628965 hasConcept C2993143319 @default.
• W2071628965 hasConcept C3013748606 @default.
• W2071628965 hasConcept C71924100 @default.
• W2071628965 hasConcept C91375879 @default.
• W2071628965 hasConcept C99454951 @default.
• W2071628965 hasConceptScore W2071628965C142462285 @default.
• W2071628965 hasConceptScore W2071628965C159047783 @default.
• W2071628965 hasConceptScore W2071628965C165901193 @default.
• W2071628965 hasConceptScore W2071628965C203014093 @default.
• W2071628965 hasConceptScore W2071628965C205649164 @default.
• W2071628965 hasConceptScore W2071628965C2776225656 @default.
• W2071628965 hasConceptScore W2071628965C2779357621 @default.
• W2071628965 hasConceptScore W2071628965C2993143319 @default.
• W2071628965 hasConceptScore W2071628965C3013748606 @default.
• W2071628965 hasConceptScore W2071628965C71924100 @default.
• W2071628965 hasConceptScore W2071628965C91375879 @default.
• W2071628965 hasConceptScore W2071628965C99454951 @default.
• W2071628965 hasIssue "5" @default.
• W2071628965 hasLocation W20716289651 @default.
• W2071628965 hasLocation W20716289652 @default.
• W2071628965 hasLocation W20716289653 @default.
• W2071628965 hasLocation W20716289654 @default.
• W2071628965 hasLocation W20716289655 @default.
• W2071628965 hasOpenAccess W2071628965 @default.
• W2071628965 hasPrimaryLocation W20716289651 @default.
• W2071628965 hasRelatedWork W1945359667 @default.
• W2071628965 hasRelatedWork W2071428655 @default.
• W2071628965 hasRelatedWork W2071628965 @default.
• W2071628965 hasRelatedWork W2121229005 @default.
• W2071628965 hasRelatedWork W2140412799 @default.
• W2071628965 hasRelatedWork W2186906753 @default.
• W2071628965 hasRelatedWork W2321454061 @default.
• W2071628965 hasRelatedWork W2438408057 @default.

• next